Skip to main content
Log in

Statins: the new aspirin?

  • Published:
Cellular and Molecular Life Sciences CMLS Aims and scope Submit manuscript

Abstract.

3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, have been described as the principal and the most effective class of drug to reduce serum cholesterol levels. Statin therapies have been shown to reduce cardiovascular events, including myocardial infarction, stroke, and death, significantly, by altering vascular atherosclerosis development in patients with or without coronary artery disease symptoms. Extensive use of statins has led to the increase of some undesirable effects that are heavily counterbalanced by the benefits. Indeed, pleiotropic effects extend far beyond cholesterol reduction and involve non-lipid-related mechanisms that modify endothelial functions, immunoinflammatory responses, smooth muscle cell activation, proliferation and migration, atherosclerotic plaque stability, and thrombus formation. In this review, we describe in detail the targets and mechanisms of action of statins.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Received 6 June 2002; received after revision 6 September 2002; accepted 6 September 2002

RID="*"

ID="*"Corresponding author.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Veillard, N., Mach, F. Statins: the new aspirin?. CMLS, Cell. Mol. Life Sci. 59, 1771–1786 (2002). https://doi.org/10.1007/PL00012505

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/PL00012505

Navigation